^
    CANCER:

    Peripheral T-cell Lymphoma





    Show legend
    Group by Gene:
    Include preclinical:

    ceritinib
    		0
    ALK inhibitor
    alectinib
    crizotinib
    1
    HDAC inhibitor
    belinostat
    romidepsin
    2
    IL-2 stimulant
    denileukin diftitox
    3
    Alkylating agent
    cyclophosphamide
    4
    Proteasome inhibitor
    bortezomib
    5
    DNA replication inhibitor
    bendamustine
    6
    CD52 inhibitor
    alemtuzumab
    7
    THF dehydrogenase inhibitor
    pralatrexate
    8
    DNA synthesis inhibitor
    gemcitabine
    9
    Topoisomerase II inhibitor
    etoposide IV
    pembrolizumab
    		10
    PD1 inhibitor
    geptanolimab
    nivolumab
    11
    PIK3CA inhibitor, PI3Kδ inhibitor
    copanlisib
    12
    CDK9 inhibitor
    SLS009
    13
    STAT3 protein degrader
    KT-333
    14
    JAK1 inhibitor
    DZD4205
    15
    CD20 inhibitor
    rituximab
    16
    CXCL12 inhibitor, Farnesyl transferase inhibitor
    tipifarnib
    CVAD
    CHOP
    GVD
    GDP
    DICE
    GemOx
    ICE
    		17
    Chemotherapy
    DHAP
    DHAX
    CEOP-E
    CHOEP
    EPOCH
    ESHAP
    BV-ICE
    CMOP
    CHEP-BV
    18
    CD30-targeted antibody-drug conjugate, Microtubule inhibitor
    brentuximab vedotin
    TEQ102
    19
    JAK1 inhibitor, JAK2 inhibitor
    ruxolitinib
    20
    PI3Kγ inhibitor, PI3Kδ inhibitor
    duvelisib
    21
    Topoisomerase II inhibitor, Alkylating agent
    cyclophosphamide + etoposide IV
    22
    TNFα inhibitor, IL-12 inhibitor, IL-6 inhibitor
    lenalidomide
    23
    Tubulin polymerization promoter, DNA synthesis inhibitor, DNA-directed DNAP inhibitor
    carboplatin + cytarabine
    24
    ROS1 inhibitor, ALK inhibitor
    lorlatinib
    25
    ALK inhibitor, EGFR inhibitor
    brigatinib
    26
    SIK3 inhibitor, PI3K inhibitor, PI3Kγ inhibitor, PI3Kδ inhibitor
    RP6530
    27
    HDAC inhibitor, MAPK inhibitor, HDAC10 inhibitor, HDAC1 inhibitor, PI3K inhibitor, HDAC2 inhibitor, AKT inhibitor, HDAC3 inhibitor
    chidamide
    28
    DNMT inhibitor, Chemotherapy
    CHOP + azacitidine oral
    29
    CD30 inhibitor, CD16A agonist
    AFM13
    30
    TNFα inhibitor, IL-12 inhibitor, CD30-targeted antibody-drug conjugate, IL-6 inhibitor, Microtubule inhibitor, CD20 inhibitor
    rituximab + lenalidomide + brentuximab vedotin
    31
    ALK inhibitor, PP2A inhibitor
    crizotinib + LB-100
    32
    CD38 inhibitor, CD3 agonist, CD28 agonist
    SAR442257
    No biomarker
    ALK positive
    TNFRSF8 expression
    TNFRSF8 negative
    TNFRSF8 positive
    CD20 overexpression
    IL2RA expression
    PD-L1 overexpression
    PD-1 overexpression
    RHOA mutation
    IDH2 mutation
    TSC2 mutation
    RPS6 underexpression
    CXCL12 expression
    TET2 mutation
    IL10-L
    TNFA-L
    CCL20-L
    IL10 elevation
    CD38 expression
    Chr del(17p)
    DNMT3A mutation
    CD28 expression
    TP53 mutation
    TP53 deletion